RecruitingNot ApplicableNCT06783816

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

A Multicenter, Single Arm, Open Label Clinical Study on the Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

Sponsor

Shanxi Bethune Hospital

Enrollment

45 participants

Start Date

Dec 1, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Lymphocytic Leukemia

Summary

The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of immune cell therapy called CAR-T — specially engineered immune cells that also produce a protein called IL-15 to help them last longer — for people with certain blood cancers that haven't responded to other treatments. **You may be eligible if...** - You are between 15 and 80 years old - You have a blood cancer (such as leukemia or lymphoma) that tests positive for CD19, CD22, or BCMA markers - Your cancer has relapsed or not responded to standard treatments - You are able to give informed consent **You may NOT be eligible if...** - Your cancer does not have the required markers - You have had severe reactions to immune therapies in the past - You have major organ problems that prevent treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGchimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Locations(1)

Shanxi Bethune Hospital

Taiyuan, Shanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06783816

Related Trials

Pilot Imaging Study of Leukemia

NCT036339553 locations

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT0393437223 locations

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

NCT018904861 location

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

NCT064817356 locations

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT054425151 location